Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

ZEB 1‐associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat

by Culig, Zoran , Stemmler, Marc P , Bronsert, Peter , Küsters, Simon , Wellner, Ulrich , Mock, Kerstin , Schüler, Julia , Burk, Ulrike , Lehmann, Waltraut , Berthold, Maria , Keck, Tobias , Weber, Anika , Preca, Bogdan‐Tiberius , Meidhof, Simone , Ruh, Manuel , Lübbert, Michael , Brabletz, Simone , Brabletz, Thomas , Puhr, Martin , Hopt, Ulrich T

in Cancer therapies / Chemotherapy / Cloning / Drug resistance / Epigenetics / Experiments / Genotype & phenotype / Histone deacetylase / Medical research / Mesenchyme / MicroRNAs / Pancreatic cancer / Phenotypes / Prostate cancer / Recovery of function / Solid tumors / Stem cells / Substance abuse treatment

2015

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

ZEB 1‐associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat

2015

Confirm

Do you wish to request the book?

ZEB 1‐associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat

2015

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

ZEB 1‐associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat

Culig, Zoran,

Stemmler, Marc P,

Bronsert, Peter,

Küsters, Simon,

Wellner, Ulrich,

Mock, Kerstin,

Schüler, Julia,

Burk, Ulrike,

Lehmann, Waltraut,

Berthold, Maria,

Keck, Tobias,

Weber, Anika,

Preca, Bogdan‐Tiberius,

Meidhof, Simone,

Ruh, Manuel,

Lübbert, Michael,

Brabletz, Simone,

Brabletz, Thomas,

Puhr, Martin,

Hopt, Ulrich T

2015

Overview

Therapy resistance is a major clinical problem in cancer medicine and crucial for disease relapse and progression. Therefore, the clinical need to overcome it, particularly for aggressive tumors such as pancreatic cancer, is very high. Aberrant activation of an epithelial–mesenchymal transition (EMT) and an associated cancer stem cell phenotype are considered a major cause of therapy resistance. Particularly, the EMT‐activator ZEB1 was shown to confer stemness and resistance. We applied a systematic, stepwise strategy to interfere with ZEB1 function, aiming to overcome drug resistance. This led to the identification of both its target gene miR‐203 as a major drug sensitizer and subsequently the class I HDAC inhibitor mocetinostat as epigenetic drug to interfere with ZEB1 function, restore miR‐203 expression, repress stemness properties, and induce sensitivity against chemotherapy. Thereby, mocetinostat turned out to be more effective than other HDAC inhibitors, such as SAHA, indicating the relevance of the screening strategy. Our data encourage the application of mechanism‐based combinations of selected epigenetic drugs with standard chemotherapy for the rational treatment of aggressive solid tumors, such as pancreatic cancer.

Share this book

Add to My Shelf

Publisher

EMBO Press

Subject

/ Cloning

/ Genotype & phenotype